There were a series of really interesting trials in the orals, most of them dealing with a drug called catequentinib or worldwide also known as inlotinib. One was a trial with epirubicin and inlotinib which clearly had an overall survival benefit. One was a trial with inlotinib and aurabulin and then was the randomized single agent American single agent approval trial of catequentinib against placebo for leiomyosarcoma...
There were a series of really interesting trials in the orals, most of them dealing with a drug called catequentinib or worldwide also known as inlotinib. One was a trial with epirubicin and inlotinib which clearly had an overall survival benefit. One was a trial with inlotinib and aurabulin and then was the randomized single agent American single agent approval trial of catequentinib against placebo for leiomyosarcoma. And so between these three presentations, there’s a really interesting signal for a new TKI that we’re hoping will get into the American population, the European population, it’s already approved in China. And so this is an active agent and figuring out how best to use this, what to combine it with and how to get it to the right patient population is now ongoing. And then Emily Slotkin presented some novel rare tumor research which looked at 16 patients with Desmoplastic Small Round Cell Tumor and TDX. And this clearly looks like a path forward within rare tumors. This wasn’t a trial. This was just 16 patients treated with this off-label at Memorial Sloan Kettering. But the data was really compelling. And so I think this is going to lead to trials in this area in sarcoma with TDX, which I’m really excited to see. Thank you.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
